SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-041619
Filing Date
2024-04-04
Accepted
2024-04-04 08:30:55
Documents
13
Period of Report
2024-04-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K cadl-20240404.htm   iXBRL 8-K 51754
2 EX-99.1 cadl-ex99_1.htm EX-99.1 41430
3 GRAPHIC img160460863_0.jpg GRAPHIC 34160
  Complete submission text file 0000950170-24-041619.txt   270456

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cadl-20240404.xsd EX-101.SCH 27879
16 EXTRACTED XBRL INSTANCE DOCUMENT cadl-20240404_htm.xml XML 4884
Mailing Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494
Business Address 117 KENDRICK STREET SUITE 450 NEEDHAM MA 02494 617-916-5445
Candel Therapeutics, Inc. (Filer) CIK: 0001841387 (see all company filings)

IRS No.: 522214851 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40629 | Film No.: 24821722
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)